Table 2.
Demographic and clinical characteristics of the MS patients treated with IFNβ.
| Treated MS patients (n = 36) | p value | ||
|---|---|---|---|
| Without clinical activity (n = 26) | With clinical activity (n = 10) | ||
| Female/Male ratio (% female) | 13/13 (50%) | 8/2 (80%) | n.s. |
| Age in yearsa | 40.32 ± 7.86 | 33.60 ± 14.64 | n.s. |
| Age at onset in yearsa | 33.15 ± 9.95 | 25.18 ± 9.78 | 0.039 |
| Disease duration (years)a | 7.32 ± 6.55 | 9.24 ± 6.48 | n.s. |
| Treatment duration (years)a | 1.23 ± 0.09 | 1.21 ± 0.10 | n.s. |
| EDSS Score at baselineb | 1.0 (0.0–1.6) | 1.7 (1.0–2.4) | n.s. |
| EDSS after one year of treatmentb | 1.0 (0.0–1.6) | 1.5 (1.0–3.6) | 0.038 |
| Relapses in the year prior to treatmentb | 1.0 (0.0–1.0) | 1.0 (0.5–1.5) | n.s. |
| Relapses after one year of treatmentb | 0.0 (0.0–0.0) | 1.0 (1.0–1.0) | 3.3 × 10−9 |
aData are expressed as mean ± standard deviation unless otherwise stated. bData are expressed as median (IR); IR: Interquartile Range. EDSS: Expanded Disability Status Scale. n.s.: not significant.